Beyond 2024, we think Roche is capable of mid- or even high-single-digit annual growth (and core operating margins remaining in the mid-30s), with higher growth possible if these in-licensed programsor in-house programs like Alzheimers disease drug candidate trontinemab or oncology drug candidate tiragolumabreach the market
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation
The peptide also demonstrates protection against corticosteroid-induced tendon damage, which is particularly relevant for athletes who have received steroid injections
n-o , Relationship between peptide half-life 36 and percent residual 13 C heavy-labeling in cystine-free/ 12 C-GSH-supplemented medium at 96 h
JOHN GILL has made 2 purchases buying 21,700 shares for an estimated $82,599 and 0 sales
Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following CARNITOR administration, mostly in patients with end stage renal disease who are undergoing dialysis
